Summit Therapeutics SMMT Q1 2026 Earnings Miss EPS 024 vs 018 Expected OPAL Fuels OPAL Q1 2026 Earnings Miss by Significant Key Takeaways AA Mission YCY Holds 1013 Direction Awaited 20260518 Inovio Pharmaceuticals INO Holds 122 Direction Awaited 20260519 ITT ITT Reports Strong Q1 2026 Revenue NA EPS Beats PAR PAR Steady at 1450 Awaiting Next Catalyst 20260515 Eagle EFSI Holds 3759 Direction Awaited 20260515 Amgen Price Target Reduced at Piper Sandler but LongTerm Outlook Remains Positive